Table 2.
Pretreatment characteristics
| Patient or Tumor Characteristic | ≤3 wk | >3–4 wk | >4 wk | P-value | |||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Days from surgery to start of RT | |||||||
| Median | 19 | 26 | 33 | ||||
| Min–Max | 0–21 | 22–28 | 29–68 | ||||
| Q1–Q3 | 16–21 | 24–27 | 31–35 | ||||
| RT dose | 0.42** | ||||||
| Median | 60 | 60 | 60 | ||||
| Min–Max | 22–60.14 | 4–64 | 2–62 | ||||
| Q1–Q3 | 60–60 | 60–60 | 60–60 | ||||
| Age, y | 0.24** | ||||||
| Median | 59 | 58 | 57 | ||||
| Min–Max | 22–87 | 19–84 | 20–84 | ||||
| Q1–Q3 | 51–66 | 50–65 | 50–65 | ||||
| Sex | 0.21* | ||||||
| Male | 105 | 56.5 | 286 | 61.6 | 423 | 56.8 | |
| Female | 81 | 43.5 | 178 | 38.4 | 322 | 43.2 | |
| Karnofsky performance status | 0.32* | ||||||
| 60 | 11 | 5.9 | 17 | 3.7 | 33 | 4.4 | |
| 70 | 23 | 12.4 | 57 | 12.3 | 89 | 11.9 | |
| 80 | 37 | 19.9 | 115 | 24.8 | 152 | 20.4 | |
| 90 | 87 | 46.8 | 183 | 39.4 | 311 | 41.7 | |
| 100 | 28 | 15.1 | 92 | 19.8 | 160 | 21.5 | |
| Surgery | Partial vs total resection | 0.003* | |||||
| Partial resection | 82 | 44.1 | 171 | 36.9 | 346 | 46.4 | |
| Total resection | 89 | 47.8 | 277 | 59.7 | 373 | 50.1 | |
| Other | 15 | 8.1 | 16 | 3.4 | 26 | 3.5 | |
| Neurologic function | No vs minor vs moderate/severe symptoms | 0.04* | |||||
| No symptoms | 46 | 24.7 | 141 | 30.4 | 260 | 34.9 | |
| Minor symptoms | 101 | 54.3 | 218 | 47.0 | 320 | 43.0 | |
| Moderate symptoms | 39 | 21.0 | 103 | 22.2 | 161 | 21.6 | |
| Severe symptoms | 0 | 0.0 | 2 | 0.4 | 4 | 0.5 | |
| RPA | RPA III vs IV vs V | 0.53* | |||||
| III | 28 | 15.1 | 77 | 16.6 | 138 | 18.5 | |
| IV | 111 | 59.7 | 288 | 62.1 | 450 | 60.4 | |
| V | 47 | 25.3 | 96 | 20.7 | 152 | 20.4 | |
| Unknown | 0 | 0.0 | 3 | 0.6 | 5 | 0.7 | |
| MGMT status | Methylated vs unmethylated | 0.70* | |||||
| Methylated | 46 | 24.7 | 120 | 25.9 | 209 | 28.1 | |
| Unmethylated | 105 | 56.5 | 267 | 57.5 | 422 | 56.6 | |
| Unknown (indeterminate, invalid) | 16 | 8.6 | 31 | 6.7 | 49 | 6.6 | |
| Insufficient tissue | 18 | 9.7 | 40 | 8.6 | 57 | 7.7 | |
| Not done | 1 | 0.5 | 6 | 1.3 | 8 | 1.1 | |
| Radiotherapy delivery declared at registration | <0.001* | ||||||
| RTOG RT# | 178 | 95.7 | 438 | 94.4 | 618 | 83.0 | |
| EORTC RT## | 8 | 4.3 | 26 | 5.6 | 127 | 17.0 | |
| Study number | <0.001* | ||||||
| RTOG 0525 | 173 | 93.0 | 345 | 74.4 | 561 | 75.3 | |
| RTOG 0825 | 13 | 7.0 | 119 | 25.6 | 184 | 24.7 | |
| Total | 186 | 100.0 | 464 | 100.0 | 745 | 100.0 | |
*Chi-square test.
**Kruskal–Wallis test.
# RTOG RT: RTOG radiation guidelines assume a 2-phase plan (46 + 14 = 60 Gy), with a wider field in most cases, that includes the “edema”/infiltrative non-enhancing tumor: T2 area of hyperintensivity + T1 enhancing residual tumor + resection cavity + a 2 cm margin.
## EORTC RT: EORTC radiation guidelines assume a 1-phase planned clinical target volume to treat T1 enhancing residual tumor + resection cavity + a 2–3 cm margin.